Sucampo Pharmaceuticals, Inc. (SCMP) said it obtained approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation, or CIC, and associated symptoms in adults, when response to diet and other non-pharmacological measures are inappropriate.
Ryuji Ueno, chief executive officer of Sucampo, commented, "The approval of AMITIZA in the U.K. is an important step in Sucampo's comprehensive initiative to increase the global reach of AMITIZA. We look forward to expanding the AMITIZA franchise into additional indications, such as opioid induced constipation, and geographic locations so that more patients can access this breakthrough medication."
For comments and feedback: editorial@rttnews.com